- Home
- TSBX vs BTAI Comparison
TSBX vs BTAI Comparison
Compare TSBX & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSBX
- BTAI
- Stock Information
- Founded
- TSBX 2015
- BTAI 2017
- Country
- TSBX United States
- BTAI United States
- Employees
- TSBX N/A
- BTAI N/A
- Industry
- TSBX
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- TSBX
- BTAI Health Care
- Exchange
- TSBX Nasdaq
- BTAI Nasdaq
- Market Cap
- TSBX 7.7M
- BTAI 8.4M
- IPO Year
- TSBX 2023
- BTAI 2018
- Fundamental
- Price
- TSBX $0.36
- BTAI $1.84
- Analyst Decision
- TSBX Buy
- BTAI Buy
- Analyst Count
- TSBX 3
- BTAI 5
- Target Price
- TSBX $4.75
- BTAI $42.60
- AVG Volume (30 Days)
- TSBX 625.8K
- BTAI 436.1K
- Earning Date
- TSBX 05-08-2025
- BTAI 08-05-2025
- Dividend Yield
- TSBX N/A
- BTAI N/A
- EPS Growth
- TSBX N/A
- BTAI N/A
- EPS
- TSBX N/A
- BTAI N/A
- Revenue
- TSBX N/A
- BTAI $1,852,000.00
- Revenue This Year
- TSBX N/A
- BTAI $5.03
- Revenue Next Year
- TSBX N/A
- BTAI $291.01
- P/E Ratio
- TSBX N/A
- BTAI N/A
- Revenue Growth
- TSBX N/A
- BTAI 5.47
- 52 Week Low
- TSBX $0.29
- BTAI $1.17
- 52 Week High
- TSBX $3.05
- BTAI $25.92
- Technical
- Relative Strength Index (RSI)
- TSBX 56.52
- BTAI 64.53
- Support Level
- TSBX $0.32
- BTAI $1.17
- Resistance Level
- TSBX $0.38
- BTAI $1.48
- Average True Range (ATR)
- TSBX 0.03
- BTAI 0.13
- MACD
- TSBX 0.00
- BTAI 0.06
- Stochastic Oscillator
- TSBX 78.89
- BTAI 100.00
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.